| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,||
*
Department of Clinical Virology, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden;
Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya;
Department of Clinical Virology, Swedish Institute for Infectious Disease Control, Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden;
§
Immunobiology of HIV Unit, San Raffaele Scientific Institute, Milan, Italy;
¶
Division of Infectious Diseases, L. Sacco Hospital, Disp-Lita Viaeba, Milan, Italy; and
||
Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
HIV-1-specific IgA has been described in the genital tract and plasma of HIV-1 highly exposed, persistently seronegative (HEPS) individuals, and IgA from these sites has been shown to neutralize HIV-1. This study examines the ability of IgA isolated from HEPS individuals to inhibit transcytosis across a tight epithelial cell layer. A Transwell system was established to model HIV-1 infection across the human mucosal epithelium. The apical-basolateral transcytosis of primary HIV-1 isolates across this mucosal model was examined in the presence and the absence of IgA isolated from the genital tract, saliva, and plasma of HEPS individuals enrolled in both a sex worker cohort in Nairobi, Kenya, and a discordant couple cohort in Italy. In the absence of IgA, HIV-1 primary isolates were actively transported across the epithelial membrane and were released on the opposite side of the barrier. These transcytosed HIV-1 particles retained their ability to infect human mononuclear cells. However, IgA purified from the mucosa and plasma of HEPS individuals was able to inhibit HIV-1 transcytosis. Inhibition was seen in three of six cervicovaginal fluid samples, five of 10 saliva samples, and three of six plasma samples against at least one of the two primary HIV-1 isolates tested. IgA from low risk, healthy control subjects had no inhibitory effect on HIV-1 transcytosis. The ability of mucosal and plasma IgA to inhibit HIV-1 transcytosis across the mucosal epithelium may represent an important mechanism for protection against the sexual acquisition of HIV-1 infection in HEPS individuals.
This article has been cited by other articles:
|
|
 |
|
  A. Wright, M. E. Lamm, and Y. T. Huang Excretion of Human Immunodeficiency Virus Type 1 through Polarized Epithelium by Immunoglobulin A J. Virol., December 1, 2008; 82(23): 11526 - 11535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Coutant, H. Yu, M.-J. Clement, A. Alfsen, F. Toma, P. A. Curmi, and M. Bomsel Both lipid environment and pH are critical for determining physiological solution structure of 3-D-conserved epitopes of the HIV-1 gp41-MPER peptide P1 FASEB J, December 1, 2008; 22(12): 4338 - 4351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Lewis, R. J. Pleass, M. R. Batten, J. D. Atkin, and J. M. Woof Structural Requirements for the Interaction of Human IgA with the Human Polymeric Ig Receptor J. Immunol., November 15, 2005; 175(10): 6694 - 6701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. T. Huang, A. Wright, X. Gao, L. Kulick, H. Yan, and M. E. Lamm Intraepithelial Cell Neutralization of HIV-1 Replication by IgA J. Immunol., April 15, 2005; 174(8): 4828 - 4835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lopalco, C. Barassi, C. Paolucci, D. Breda, D. Brunelli, M. Nguyen, J. Nouhin, T. T. Luong, L. X. Truong, M. Clerici, et al. Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin J. Gen. Virol., February 1, 2005; 86(2): 339 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Devito, B. Zuber, U. Schroder, R. Benthin, K. Okuda, K. Broliden, B. Wahren, and J. Hinkula Intranasal HIV-1-gp160-DNA/gp41 Peptide Prime-Boost Immunization Regimen in Mice Results in Long-Term HIV-1 Neutralizing Humoral Mucosal and Systemic Immunity J. Immunol., December 1, 2004; 173(11): 7078 - 7089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Matoba, A. Magerus, B. C. Geyer, Y. Zhang, M. Muralidharan, A. Alfsen, C. J. Arntzen, M. Bomsel, and T. S. Mor A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs PNAS, September 14, 2004; 101(37): 13584 - 13589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Stevens, K. E. Howard, S. Nordone, M. Burkhard, and G. A. Dean Oral Immunization with Recombinant Listeria monocytogenes Controls Virus Load after Vaginal Challenge with Feline Immunodeficiency Virus J. Virol., August 1, 2004; 78(15): 8210 - 8218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Garulli, Y. Kawaoka, and M. R. Castrucci Mucosal and Systemic Immune Responses to a Human Immunodeficiency Virus Type 1 Epitope Induced upon Vaginal Infection with a Recombinant Influenza A Virus J. Virol., January 15, 2004; 78(2): 1020 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lemiale, W.-p. Kong, L. M. Akyurek, X. Ling, Y. Huang, B. K. Chakrabarti, M. Eckhaus, and G. J. Nabel Enhanced Mucosal Immunoglobulin A Response of Intranasal Adenoviral Vector Human Immunodeficiency Virus Vaccine and Localization in the Central Nervous System J. Virol., September 15, 2003; 77(18): 10078 - 10087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Hladik, A. Desbien, J. Lang, L. Wang, Y. Ding, S. Holte, A. Wilson, Y. Xu, M. Moerbe, S. Schmechel, et al. Most Highly Exposed Seronegative Men Lack HIV-1-Specific, IFN-{gamma}-Secreting T Cells J. Immunol., September 1, 2003; 171(5): 2671 - 2683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. I. Albu, A. Jones-Trower, A. M. Woron, K. Stellrecht, C. C. Broder, and D. W. Metzger Intranasal Vaccination Using Interleukin-12 and Cholera Toxin Subunit B as Adjuvants To Enhance Mucosal and Systemic Immunity to Human Immunodeficiency Virus Type 1 Glycoproteins J. Virol., May 15, 2003; 77(10): 5589 - 5597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Bradney, G. D. Sempowski, H.-X. Liao, B. F. Haynes, and H. F. Staats Cytokines as Adjuvants for the Induction of Anti-Human Immunodeficiency Virus Peptide Immunoglobulin G (IgG) and IgA Antibodies in Serum and Mucosal Secretions after Nasal Immunization J. Virol., January 15, 2002; 76(2): 517 - 524. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
